Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
This approval makes Eli Lillys oral GLP-1 receptor agonist, to be marketed as Foundayo, the second GLP-1 drug for weight loss available in pill form, after Wegovy, which gained approval in December 2025
Tirzepatide has a higher affinity with GLP-1R than GLP-1 does (pIC 50 : 8.90 vs 8.62), and its cAMP activation activity is significantly lower (12 decrease in pEC 50 )
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino acid pentadecapeptide derived from a protective protein found in human gastric juice
Another crucial mechanism is its ability to enhance insulin signaling in the brain
2025-11-15
It adds that fasting state, medication history, and concurrent GI conditions also shape timing
US$ 27.80
US$ 25.80
US$ 22.65
